LTR Pharma Limited (ASX:LTP)

Australia flag Australia · Delayed Price · Currency is AUD
0.450
0.00 (0.00%)
At close: Mar 6, 2026
-21.05%
Market Cap 81.80M
Revenue (ttm) 1.13M
Net Income (ttm) -8.95M
Shares Out 181.78M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 131,346
Average Volume 207,249
Open 0.450
Previous Close 0.450
Day's Range 0.435 - 0.455
52-Week Range 0.270 - 0.810
Beta 3.89
RSI 40.53
Earnings Date Feb 26, 2026

About LTR Pharma

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol LTP
Full Company Profile

Financial Performance

In fiscal year 2025, LTR Pharma's revenue was 1.51 million, an increase of 2978.25% compared to the previous year's 49,002. Losses were -5.59 million, -19.57% less than in 2024.

Financial Statements

News

There is no news available yet.